COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Single administration of intracameral bimatoprost implant: IOP lowering, safety

Name: Single administration of intracameral bimatoprost implant: IOP lowering, safety
Uploaded: 2020-12-02T07:00:00.000Z
Description: Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

December 2, 2020

David Hutton
Alex Delaney-Gesing

Video

Conferences|AAO

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

See more AAO coverage here